Home > Haematology > EHA 2021 > Lymphoma > ZUMA-5 vs SCHOLAR-5: Axicabtagene ciloleucel significantly improves FL outcome

ZUMA-5 vs SCHOLAR-5: Axicabtagene ciloleucel significantly improves FL outcome

Presented By
Prof. John Gribben, Barts Cancer Institute, UK
Conference
EHA 2021
Trial
ZUMA-5; SCHOLAR-5
Updated results from the ZUMA-5 trial showed that treatment with axicabtagene ciloleucel resulted in significantly higher efficacy in patients with relapsed/refractory (r/r) follicular lymphoma (FL) compared with real-world treatment patterns from the SCHOLAR-5 control cohort. These results support that axicabtagene ciloleucel treatment represents a significant improvement in treatment options for these patients. Prof. John Gribben (Barts Cancer Institute, UK) presented updated results of the ZUMA-5 study (NCT03105336), a prospective, interventional study of axicabtagene ciloleucel (axi-cel) in patients with r/r follicular lymphoma who have failed ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on